Escitalopram Oxalate
Product Images NDC 70934-163

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Escitalopram Oxalate (NDC 70934-163). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Denton Pharma, Inc. Dba Northwind Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

70934 163 30 Master Bottle Label Approval Rev B 01 19

This is a prescription drug with National Drug Code (NDC) 70934-163-30. The name of the drug is Escitalopram. It is available in the form of tablets, USP and each tablet contains 10mg of the drug. The package contains 30 tablets. The remaining text seems to be unreadable or gibberish.*

FDA Label Image

1 (A659eec9 07cf 4399 Abab 7e8036d8b6ad 01)

This is a table detailing the frequency of adverse reactions observed in patients with Major Depressive Disorder in response to treatment with escitalopram oxalate compared to placebo. The adverse reactions observed with a frequency of more than 2% and higher than placebo are listed in the table. These reactions include dry mouth, sweating, diarrhea, constipation, abdominal pain, influenza-like symptoms, fatigue, insomnia, decreased appetite, decreased libido, rhinitis, sinusitis, ejaculation disorder, impotence, and anorgasmia. There is a note specifying the denominators used for males and females in relation to sexual adverse reactions.*

FDA Label Image

2 (A659eec9 07cf 4399 Abab 7e8036d8b6ad 02)

This is a table showing the treatment-emergent adverse reactions observed in patients with generalized anxiety disorder. It lists various adverse reactions along with the frequency of their occurrences for patients who were treated with Escitalopram and placebo. Adverse reactions with a frequency greater than 2% and greater than placebo are mentioned. These adverse reactions are broadly categorized into Autonomic Nervous System Disorders, Central and Peripheral Nervous System Disorders, Gastrointestinal Disorders, General, Musculoskeletal System Disorder, Psychiatric Disorders, Respiratory System Disorders, and Trogenital. The table also provides the percentage of occurrence of each of the adverse reactions for Escitalopram and placebo treatment options, respectively.*

FDA Label Image

1 (A659eec9 07cf 4399 Abab 7e8036d8b6ad 03)

FDA Label Image

Logo (A659eec9 07cf 4399 Abab 7e8036d8b6ad 04)

FDA Label Image

1 (A659eec9 07cf 4399 Abab 7e8036d8b6ad 05)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.